WE GIVE SHAREHOLDERS A VOICE
The complaint alleges that Esperion Therapeutics, Inc. violated federal securities laws by issuing materially false and/or misleading information and/or failing to disclose material information.
If you suffered a loss in Esperion Therapeutics, Inc. you have until July 6, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.